首页|葛根芩连汤加减联合美沙拉嗪治疗大肠湿热型溃疡性结肠炎临床效果及其对肠道菌群、免疫功能和炎症水平的调节

葛根芩连汤加减联合美沙拉嗪治疗大肠湿热型溃疡性结肠炎临床效果及其对肠道菌群、免疫功能和炎症水平的调节

扫码查看
目的 观察葛根芩连汤加减联合美沙拉嗪治疗大肠湿热型溃疡性结肠炎的临床效果及其对患者肠道菌群、免疫功能和炎症水平的调节作用.方法 选择2020年1月—2022年12月在医院消化内科治疗的100例溃疡性结肠炎患者作为研究对象,按照随机数字表法将患者平均分为美沙拉嗪组和葛根芩连组,各组50例,美沙拉嗪组患者单纯口服美沙拉嗪治疗,葛根芩连组患者在美沙拉嗪组基础上联合葛根芩连汤加减治疗.观察两组患者的临床效果和不良反应情况,并比较干预前后血清炎症因子、免疫功能以及肠道菌群变化.结果 美沙拉嗪组患者的有效率为80.00%(40/50),葛根芩连组患者的有效率为94.00%(47/50),与美沙拉嗪组比较,葛根芩连组的有效率明显升高(P<0.05).干预4周后,与美沙拉嗪组比较,葛根芩连组患者的血清白介素(IL)-6、IL-8、γ-干扰素(IFN-γ)以及肿瘤坏死因子-a(TNF-α)水平均明显下降(P<0.01);葛根芩连组患者外周血中CD3+、CD4+以及CD4+/CD2+水平明显升高,而CD8+水平则明显下降(P<0.01).且葛根芩连组患者肠道双歧杆菌、乳酸杆菌以及肠球菌水平相较于美沙拉嗪组均明显升高,差异具有统计学意义(P<0.01).干预4周后,葛根芩连组患者的IBDQ评分和SF-36评分相较于美沙拉嗪组均明显升高,差异具有统计学意义(P<0.01).治疗期间两组患者的主要不良反应有腹胀、消化不良、头晕头痛、乏力、皮疹等,美沙拉嗪组和葛根芩连组的不良反应总发生率分别为10.00%(5/50)、14.00%(7/50),差异无统计学意义(P>0.05).结论 葛根芩连汤加减联合美沙拉嗪能够提高大肠湿热型溃疡性结肠炎患者的临床疗效,抑制血清炎症水平,调节机体免疫功能,其作用机制与调节患者肠道菌群平衡有关.
Clinical Effect of Gegen Qinlian Decoction(葛根芩连汤)Combined with Mesalazine in Treatment of Damp-Heat Ulcerative Colitis of Large Intestine and Its Regulation of Intestinal Flora,Immune Function and Inflammation
Objective To observe the clinical effects of Gegen Qinlian Decoction(葛根芩连汤)combined with mesalazine in the treatment of damp-heat ulcerative colitis of large intestine and its regulatory effects on intestinal flora,immune function and inflammation.Method A total of 100 patients with ulcerative colitis treated in gastroenterology department of the hospital from Jan-uary 2020 to December 2022 were selected as research objects.According to random number table method,the patients were e-venly divided into mesalazine group and Gegen Qinlian Decoction group,with 50 cases in each group.Those in the mesalazine group were treated by oral mesalazine alone.Gegen Qinlian Decoction group was treated with mesalazine group and Gegen Qinlian Decoction.The clinical effects and adverse reactions of the two groups were observed,and the changes of serum inflammatory fac-tors,immune function and intestinal flora before and after intervention were compared.Results The effective rate was 80.00%(40/50)in mesalazine group and 94.00%(47/50)in Gegen Qinlian group.Compared with that of the mesalazine group,the ef-fective rate in Gegen Qinlian Decoction group was significantly higher(P<0.05).After 4 weeks of intervention,compared with those of the mesalazine group,serum levels of IL-6,IL-8,IFN-γ and TNF-α in Gegen Qinlian Decoction were significantly decreased(P<0.01).The levels of CD3+,CD4+and CD4+/CD8+in peripheral blood of Gegen Qinlian Decoction group were sig-nificantly increased,while the levels of CD8+were significantly decreased(P<0.01,P<0.05).The levels of intestinal bifidobacterium,lactobacillus and enterococcus in the Gegen Qinlian Decoction group were significantly higher than those in the mesalazine group,and the difference was statistically significant(P<0.01).After 4 weeks of intervention,inflammatory bowel disease patient quality of life scale(IBDQ)score and the MOS item short from health survey(SF-36)score of the Gegen Qinlian Decoction group were significantly increased compared with those in the mesalazine group(P<0.01).During treatment,the main adverse reactions in the two groups were abdominal distension,dyspepsia,dizziness,headache,fatigue,rash,etc.The total inci-dence of adverse reactions in mesalazine group and Gegen Qinlian Decoction group was 10.00%(5/50)and 14.00%(7/50),respectively,with no statistical significance(P>0.05).Conclusion Gegen Qinlian Decoction combined with mesalazine can im-prove the clinical efficacy of patients with large intestine damp-heat ulcerative colitis,inhibit the serum inflammation and regu-late the immune function,and its mechanism is related to regulating the balance of intestinal flora in patients.

Gegen Qinlian Decoction(葛根芩连汤)ulcerative colitisdamp-heat in large intestineintestinal floraim-mune functioninflammation levelsclinical research

龙鑫月、弓艳霞、唐艳萍

展开 >

天津中医药大学,天津 301617

天津市南开医院,天津 300100

葛根芩连汤 溃疡性结肠炎 大肠湿热 肠道菌群 免疫功能 炎症水平 临床研究

国家自然科学基金项目国家自然科学基金面上项目天津市卫生健康委员会、天津市中医药管理局中医中西医结合科研项目

82074231815737372021091

2024

中华中医药学刊
中华中医药学会 ,辽宁中医药大学

中华中医药学刊

CSTPCD北大核心
影响因子:1.007
ISSN:1673-7717
年,卷(期):2024.42(1)
  • 2
  • 27